DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR Return to: OCREVUS (ocrelizumab)
       *****************************************************
       #Post#: 4186--------------------------------------------------
       (ECTRIMS) Ocrevus benefit confirmed in patients over 60 with MS
       By: agate Date: October 14, 2023, 12:41 am
       ---------------------------------------------------------
       From MedPage Today (October 12, 2023)--"Ocrelizumab benefit
       confirmed in older patients with MS"--a report from the ECTRIMS
       conference (October 2023). Please note that the article runs for
       3 pages.
  HTML https://www.medscape.com/viewarticle/997332?form=fpf
       Excerpt:
       [quote]
       [font=proxima_nova_rgregular]The researchers studied about 700
       patients with multiple sclerosis aged 60 years and older from an
       international database, comparing outcomes with the anti-CD20
       monoclonal antibody ocrelizumab vs those for interferon/
       glatiramer acetate[/font] (BRACE).
       They[font=proxima_nova_rgregular] found ocrelizumab
       significantly reduced the annual rate of relapses, although
       after adjustments, patients overall faced a relapse rate of less
       than 0.1 per year. There were also no significant differences in
       either disability progression or improvement between the two
       treatments.[/font][/quote]
       *****************************************************